ABL1 and gastric cancer: By treating GC cell lines SGC-7901 and AGS with Imatinib (10 μM) and Nilotinib (5 μM) for 24 h, the levels of pABL1 decreased, accompanied with the inhibition of p-NF-κB1, p-STAT3, IL-6, IL-1β, and COX2, which meant that ABL1 regulated the inflammatory signaling pathway (Figure 3).